videos, cardiology videos, DAIC, PulseTV, pulse TV
Feature

There were more than 38,250 page views for video content on Diagnostic and Interventional Cardiology’s (DAIC) website in ...

Home December 19, 2016
Home
Videos | Radiation Dose Management

Mahadevappa Mahesh, MS, Ph.D., chief physicist and professor of radiology and radiological science at Johns Hopkins ...

Home December 19, 2016
Home
Videos | Artificial Intelligence

At RSNA 2016, the key buzzwords were “deep learning,” “machine learning” and “artificial intelligence.” Vendors and ...

Home December 19, 2016
Home
Videos | Artificial Intelligence

Mark Michalski, M.D., director of the Center for Clinical Data Science at Massachusetts General Hospital, explains the ...

Home December 19, 2016
Home
Videos | Magnetic Resonance Imaging (MRI)

Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of ...

Home December 19, 2016
Home
Videos | RSNA 2016

A post-game roundup by Imaging Technology News (ITN) Contributing Editor Greg Freiherr and Diagnostic and Interventional ...

Home December 19, 2016
Home
News | Heart Valve Technology

December 19, 2016 — BioTrace Medical Inc. announced the first commercial use of the company’s Tempo Temporary Pacing ...

Home December 19, 2016
Home
News | Pharmaceuticals

December 13, 2016 — Coupling data mining of adverse event reports and electronic health records with targeted laboratory ...

Home December 13, 2016
Home
News | Stent Grafts

Lombard Medical Inc. announced that its Altura endovascular stent graft system was featured in a scientific presentation at the 43rd annual VEITHsymposium, Nov. 15-19 in New York City. The Altura stent graft, which was launched commercially in Europe earlier in 2016, is specifically designed to simplify treatment in patients with normal abdominal aortic aneurysm (AAA) anatomy.

Home December 13, 2016
Home
News | Stents Peripheral

Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (BMS SE) at VEITHsymposium 2016, Nov. 15-19 in New York. Jos C. van den Berg, University of Bern, Switzerland, presented the encouraging interim results for Pulsar-18 in treatment of superficial femoral artery (SFA) disease during the symposium’s main program on behalf of lead investigator for the BIOFLEX PEACE all-comers trial, Michael Lichtenberg, Vascular Center, Arnsberg, Germany.

Home December 13, 2016
Home
News | Wearables

Scientists at Tokyo Institute of Technology have developed a portable and wearable terahertz scanning device for non-invasive inspection of three-dimensional objects. The device is made using arrays of carbon nanotubes and does not require bulky peripheral optical components.

Home December 13, 2016
Home
Sponsored Content | Case Study | Cardiovascular Business | By Praveen Lobo, Vice President Strategic Products – LUMEDX Corporation

The primary goal of any healthcare provider is to improve the lives of patients through effective treatment. However, because they are also businesses, hospitals have concerns that entail much more than this. To be viable in the long term, hospitals must manage their margins to fund their mission.

Home December 13, 2016
Home
News | Stents Peripheral

LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for venous arterialization of the lower limbs in end-stage patients at risk of limb amputation for critical limb ischemia (CLI).

Home December 08, 2016
Home
News | Ventricular Assist Devices (VAD)

St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial session at the American Heart Association (AHA) Scientific Sessions, Nov. 12-16 in New Orleans. The MOMENTUM 3 study compared the HeartMate 3 Left Ventricular Assist System (LVAS) to the HeartMate II LVAS in treating advanced stage heart failure, and is the largest LVAD trial in the world to evaluate both short-term and long-term patients in a single study. The study results demonstrated patients receiving the HeartMate 3 LVAS had an 86.2 percent survival rate with freedom from disabling stroke and reoperation to repair or replace the device.

Home December 08, 2016
Home
Technology | Patient Monitors

Corsens Medical Ltd. announced that it has received clearance for a Pre-Marketing Notification (510(k)) with the U.S. Food and Drug Administration (FDA) for its Corsens Cardiac Monitor (patents pending).

Home December 08, 2016
Home
Subscribe Now